Long-acting injectable (LAI) HIV pre-exposure prophylaxis (PrEP) may mitigate adherence challenges reported by young women in Southern Africa. We assessed preferences for PrEP in public-sector, primary care clinics in Swaziland. Among surveyed respondents, 75% (95% confidence interval = 65–83%) stated preference for LAI over oral PrEP; with no differences by sex, age, or sexual behavior (all P > 0.05). Notably, over 70% (95% confidence interval 58–82%) with current use of oral PrEP also stated preference for LAI PrEP.
aMassachusetts General Hospital
bHarvard Medical School, Boston, Massachusetts, USA
cMbarara University of Science and Technology, Mbarara, Uganda
dAfrica Health Research Institute, KwaZulu-Natal, South Africa
eClinton Health Access Initiative, Mbabane, Swaziland
fUniversity of California San Francisco, San Francisco, California, USA
gUniversity of Heidelberg, Heidelberg, Germany
hJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
iSwaziland Ministry of Health, Mbababane, Swaziland.
Correspondence to Mark J. Siedner, MD, MPH, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. E-mail: firstname.lastname@example.org
Received 4 April, 2018
Revised 18 April, 2018
Accepted 18 April, 2018
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).